Table 1 Patients´ characteristics
Characteristic | n = 32 |
|---|---|
Sex n (%) | |
male | 21 (66) |
female | 11 (34) |
Age (years) | |
median | 63 |
range | 44–81 |
Stadium n (%) | |
localized | 10 (31) |
metastasized | 22 (69) |
Grading n (%) | |
G2, G3 | 22 (69) |
G1 | 7 (22) |
Gxa | 3 (9) |
Cycles of doxorubicin/olaratumab administered n (%) | |
1 to 5 | 23 (72) |
6 to 8 | 9 (28) |
median no. of cycles | 4 |
Exposure to doxorubicin | |
median cumulative dose (mg/m2) | 300 |
range (mg/m2) | 75–600 |
Proportion of patients with delay of therapy due to toxicity/infection n (%) | 4 (12,5) |
Patients with previous treatment lines n (%) | |
0 | 25 (78) |
≥ 1 | 7 (32) |
Response n (%) | |
PR | 4 (13) |
SD | 7 (22) |
PD | 21 (66) |
Performance status (ECOG) n (%) | |
0 | 14 (44) |
1 | 16 (50) |
2 | 2 (6) |
Pattern of metastases n (%) | |
lung only | 3 (9) |
multiple | 6 (19) |
Site of primary tumor n (%) | |
extremity | 8 (25) |
retroperitoneum | 8 (25) |
trunc | 14 (4) |
head | 1 (3) |
uterus | 1 (3) |
Site of metastasis n (%) | |
lung | 6 (19) |
liver | 4 (13) |
bone | 2 (6) |
other | 7 (22) |